Permeability study of ciprofloxacin amd ciprofloxacion aluminiun complex through the rat small intestine in side-by-side difussion chambers

GUZMÁN, L.; BALLENT, M.; LIFSCHITZ, A.; LANUSSE, C.; BREDA, A.; MANZO, R.; OLIVERA, M.

Rosario

Congreso; XLI Reunión anual de la Asociación Argentina de Farmacología Experimental (SAFE); 2009

SAFE

The purpose of this study was to investigate the in vitro intestinal absorption process of ciprofloxacion hydrochloride (CIP) and CIP-aluminium complex (CIP-AI). The permeability was determined in side-by-side diffusion chambers in different regions of the rat small intestine. The permeability class ascertained by comparing drug tested with the low permeability internal standard, fluorescein. The apical to basolateral (AP-BL) and the BL-AP transport of the compounds was also investigated. All compounds were detected by fluorescent detector (275nm, 491nm (exitación) and 443nm, 515nm (emission) for CIP and fluorescein, respectively. CIP and CIP-AI exhibeted no segmental dependent permeability through the gut wall (p=0.05). Both drigs exhibited significantly increased in the distal ileum in comparison to the proximal regions of the intestine (p=0.05). Based on ocmparison to fluorescein, CIP and CIP-AI were classified as low permeability drugs. The results demonstrated the aluminium complexation does not limit in vitro intestinal absorption. However, the in vivo comparative bioavailabilities obtained in mice, showed that the higher solubility of CIP-AI would play a major role in CIP-AI bioavailability.